Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FGES8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,986
Award facts
- Contract value 100% obligated
- $34,985.71 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $35K to DMS Pharmaceutical Group Inc. for Jakafi 10 mg tablets (60-count units) on January 27, 2026, with an ultimate completion date of January 28, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract type with no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order was funded by the Defense Logistics Agency and executed at the vendor's Park Ridge facility.
This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that was awarded on November 13, 2025, with a $500M ceiling and completion date of December 31, 2036. The PPV-G GEN V contract positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to supply a comprehensive range of pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations globally. Jakafi, a targeted cancer therapy, represents part of the vendor's extensive portfolio of specialized pharmaceutical products delivered to military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FGES8?
SPE2DR26FGES8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FGES8 worth?
The government has obligated $34,986 on SPE2DR26FGES8.
Is contract SPE2DR26FGES8 an order under another contract?
Yes. SPE2DR26FGES8 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGES8 competed?
The extent of competition for SPE2DR26FGES8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award